Hypochromic erythrocytes (%): A reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma

Annals of Hematology

Volumn 86, Issue 5, 2007, Pages 369-376

  Katodritou, Eirini ^a   Terpos, Evangelos ^b   Zervas, Konstantinos ^a   Speletas, Matthaios ^c   Kapetanos, Dimitrios ^a   Kartsios, Charalambos ^a   Verrou, Evgenia ^a   Banti, Anastasia ^a   Effraimidou, Smaragda ^c   Christakis, John ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Anemia; Erythropoietin (rHuEPO); Iron restricted erythropoiesis; Lymphoma; Multiple myeloma

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FLUDARABINE; IRON; MELPHALAN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; THALIDOMIDE; TRANSFERRIN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; ERYTHROCYTE; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HUMAN; INTERMETHOD COMPARISON; IRON RESTRICTION; LYMPHOMA; MALE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RETICULOCYTE COUNT; TRANSFERRIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; ERYTHROCYTE INDICES; ERYTHROCYTES; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMATOCRIT; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS;

EID: 33947606834     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0258-x     Document Type: Article

References (31)

1. Alexanian R, Dimopoulos M (1994) Treatment of multiple myeloma. N Engl J Med 330:484-489
2. Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B (2005) Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol 84:159-166
3. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307
4. Beguin Y (1995) Erythropoiesis and erythropoietin in multiple myeloma. Leuk Lymphoma 18:413-421
5. Beguin Y (2005) Intravenous iron and recombinant human erythropoietin in cancer patients. J Clin Oncol 23:651-652
6. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216
7. Bovy C, Gothot A, Krzesinski JM, Y Beguin (2005) Mature erythrocyte indices: New markers of iron availability. Haematologica 90:549-551
8. Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH (1997) Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12:1173-1181
9. Cavill I (2002) Erythropoiesis and iron. Best Pract Res Clin Haematol 15:399-409
10. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434-441
11. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386-393
12. Coiffier B (2000) The impact and management of anaemia in haematological malignancies. Med Oncol 17(Suppl 1):S2-S10
13. Cucuianu A, Patiu M, Rusu A (2006) Hepcidin and multiple myeloma related anemia. Med Hypotheses 66:352-354
14. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK (1997) Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52:217-222
15. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13:461-473
16. Henry D, Abels R, Larholt K (1995) Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoietin-alpha) therapy in cancer patients. Blood 85:1676-1678
17. Katodritou E, Speletas M, Zervas K, Kapetanos D, Georgiou E, Christoforidou A, Pavlitou A, Sion M, Christakis J (2006) Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 12:47-54
18. Kyle RA (1975) Multiple myeloma: Review of 869 cases. Mayo Clin Proc 50:29-40
19. Littlewood TJ, Zagari M, Pallister C, Perkins A (2003) Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8:99-107
20. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063
21. Macdougall IC (1998) What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 13:847-849
22. Means RT Jr, Krantz SB (1992) Progress in understanding the pathogenesis of anemia of chronic disease. Blood 80:1639-1647
23. Mittelman M (2003) Implications of anemia in multiple myeloma. Clin Lymphoma 4:23-29
24. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87:2675-2682
25. Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C (1999) B-chronic lymphocytic leukemia, small lymphocytic lymphoma and lymphoplasmacytic lymphoma, including Waldestrom's macroglobulinemia: A clinical, morphologic and biologic spectrum of similar disorders. Semin Hematol 36:104-114
26. Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A, Littlewood TJ (2001) Erythropoietin: A paradigm for the development of practice guidelines. Hematology (Am Soc Hematol Educ Program) 1:10-30
27. Stasi R, Amadori S, Littlewood TJ, Terzoli E, Newland AC, Provan D (2005) Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 10:539-554
28. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G (2001) The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416-1423
29. Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066-1076
30. Thomas C, Thomas L (2005) Anemia of chronic disease: Pathophysiology and laboratory diagnosis. Lab Hematol 11:14-23
31. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011-1023